Hindman Andrew A. 4
4 · Theravance Biopharma, Inc. · Filed Nov 23, 2021
Insider Transaction Report
Form 4
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
- Tax Payment
Ordinary Shares
2021-11-19$8.36/sh−1,350$11,286→ 167,258 total
Footnotes (2)
- [F1]Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
- [F2]Includes 1228 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2021.